Annual Report on Celera (Quest) License

(PresseBox) ( Sydney, Australia, )
.
- Midkine is confirmed to be part of Celera's six marker lung cancer diagnostic panel
- New study using the test shows 94% specificity in correctly classifying non-malignant nodules
- 1.7 million smokers over 55 may be tested annually

Cellmid Limited (ASX: CDY) has received its second annual report from Celera-Quest Diagnostics in relation to its lung cancer diagnostic licence (details of the license are included at the end of this announcement). The report confirmed that midkine is one of the six biomarkers on Celera's lung cancer diagnostic panel.

Results of a recent study have also been provided by Celera-Quest Diagnostics demonstrating that the six marker lung cancer panel showed 94% specificity (at 70% sensitivity) in accurately classifying non-malignant nodules identified during CT (computed tomography) scanning of a high risk smoker population.

Even though the rate of smoking is declining there are an estimated 94 million current and past smokers in the United States who are at risk of contracting lung cancer. Of this group those aged over 55 are at greatest risk. Mortality caused by lung cancer can be markedly reduced if cancerous nodules are detected and removed very early; however it is usually the case that once patients are symptomatic, the cancer has already spread from its initial site, thereby reducing the chances of successful treatment.

Population screening of at-risk groups using imaging such as CT scanning has been proposed as one way to reduce lung cancer mortality. This proposal was recently tested by the US National Institute of Health (NIH) in a large-scale study of 53,454 current and ex- smokers aged 55-74, which found that screening by CT scanning reduced mortality by 20% in 6 years [1] .

While this is some good news for the seven million American smokers over 55, the low specificity of CT scanning is still a concern as the same study showed that 25% of the solitary nodules identified by CT scan proved to be non-cancerous after lung biopsy (75% specificity).

Unnecessary biopsy of otherwise benign nodules creates additional costs and significant morbidity for this already very large patient group. Celera-Quest Diagnostics' six marker lung cancer panel with its 94% specificity may therefore become a useful adjunct to imaging. It may assist in further clarifying the diagnosis in patients who have tested positive during their CT screening (estimated to be 1.7 million in the highest risk group).

In order to commercialize the lung cancer panel the assay is currently being transferred to a multiplex format. With Quest Diagnostics' extensive distribution capabilities it will most likely be sold as a Lab Developed Test (LDT). In addition to the specific application for high risk screening, Celera-Quest Diagnostics has confirmed that it continues with the development of additional lung cancer tests using midkine.

License between Cellmid Limited and Celera-Quest Diagnostics for lung cancer In October 2009

Cellmid Limited licensed to Celera Corporation midkine as a biomarker for the early diagnosis, prognosis and disease monitoring of lung cancer to be used in Celera's proprietary biomarker panel. The terms of the license are confidential but involve upfront and milestone payments and royalties on product sales. In May 2011 Celera Corporation was acquired by Quest Diagnostics, one of the largest diagnostics companies in the world. The acquisition was share based and did not affect the terms of the license between Celera Corporation (now Celera-Quest Diagnostics) and Cellmid Limited.

About Midkine (MK)

Midkine is a multifunctional growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, because midkine is only present in a disease context, targeting midkine does not harm normal healthy tissues.

[1] Reduced Lung-Cancer Mortality with Low Dose Computed Tomographic Screening, The N Eng J Med, vol.365 No5 4 Aug 2011
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.